Literature DB >> 17148725

A 55-year-old woman with osteopenia.

Steven R Cummings1.   

Abstract

About half of postmenopausal women have a bone density T score at the femoral neck between -1.0 and -2.5. Bone density in this range was termed "osteopenia" by a World Health Organization working group. Osteopenia is not a disease and the label can cause unnecessary anxiety. Osteopenia encompasses a wide range of fracture risks; an individual patient's risk can be estimated from her age, bone mineral density, and clinical risk factors. Regardless of bone mineral density, regular exercise and adherence with vitamin D and calcium intake may reduce the risk of hip fracture. Osteopenia by itself is not an indication for treatment. Decisions about pharmacological treatment to prevent fractures should be based on the patient's risk of fractures, evidence about the efficacy and nonskeletal effects of the specific treatment, and the patient's preferences.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17148725     DOI: 10.1001/jama.296.21.2601

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  13 in total

Review 1.  Bone Density Screening and Re-screening in Postmenopausal Women and Older Men.

Authors:  Margaret L Gourlay; Robert A Overman; Kristine E Ensrud
Journal:  Curr Osteoporos Rep       Date:  2015-12       Impact factor: 5.096

2.  Drugs for pre-osteoporosis: prevention or disease mongering?

Authors:  Pablo Alonso-Coello; Alberto López García-Franco; Gordon Guyatt; Ray Moynihan
Journal:  BMJ       Date:  2008-01-19

3.  Filtering FRAX.

Authors:  Nelson B Watts; Ethel S Siris; Steven R Cummings; Douglas C Bauer
Journal:  Osteoporos Int       Date:  2010-04       Impact factor: 4.507

Review 4.  Nitric oxide donors for the treatment of osteoporosis.

Authors:  Sophie A Jamal; Celeste J Hamilton
Journal:  Curr Osteoporos Rep       Date:  2012-03       Impact factor: 5.096

5.  Type 1 Gaucher disease: significant disease manifestations in "asymptomatic" homozygotes.

Authors:  Manisha Balwani; Laura Fuerstman; Ruth Kornreich; Lisa Edelmann; Robert J Desnick
Journal:  Arch Intern Med       Date:  2010-09-13

Review 6.  Hormone therapy for the prevention of bone loss in menopausal women with osteopenia: is it a viable option?

Authors:  Mary H Hohenhaus; Kelly A McGarry; Nananda F Col
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA.

Authors:  B Dawson-Hughes; A N A Tosteson; L J Melton; S Baim; M J Favus; S Khosla; R L Lindsay
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

8.  The effects of tibolone in older postmenopausal women.

Authors:  Steven R Cummings; Bruce Ettinger; Pierre D Delmas; Peter Kenemans; Victoria Stathopoulos; Pierre Verweij; Mirjam Mol-Arts; Lenus Kloosterboer; Lori Mosca; Claus Christiansen; John Bilezikian; Eduardo Mario Kerzberg; Susan Johnson; Jose Zanchetta; Diederich E Grobbee; Wilfried Seifert; Richard Eastell
Journal:  N Engl J Med       Date:  2008-08-14       Impact factor: 91.245

Review 9.  The effects of organic nitrates on osteoporosis: a systematic review.

Authors:  S A Jamal; L S Reid; C J Hamilton
Journal:  Osteoporos Int       Date:  2013-01-11       Impact factor: 4.507

10.  Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks.

Authors:  N D Nguyen; S A Frost; J R Center; J A Eisman; T V Nguyen
Journal:  Osteoporos Int       Date:  2008-03-07       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.